Author Archives
I studied at Adelaide Boys' High School, and the University of Adelaide, Medical School. graduating in 1961. My field of specialisation was Plastic and Reconstructive Surgery. Prior to establishing my practice in Adelaide, I spent 5 years working in India, and Papua-New Guinea, in the field of reconstructive surgery for leprosy.
In retirement I joined the Australian Technical Analyst Association and passed the two examinations for a Diploma inTechnical Analysis, and the designation Certified Financial Technician (CFTe) by the International Federation of Technical Analysts.
-
Are you better off investing your surplus funds into your residence than into Superannuation?
With the Labor Party announcing a week ago its intention to save an estimated $59 billion by abolishing cash imputation credits on dividend income, those saving for, or in retirement, might justifiably question the wisdom of putting their surplus funds… Read More ›
-
Should asset wealthy retirees receive cash imputation credits when they pay little or no income tax?
This question is looming as a key issue for voters at the next federal election. Abolition of such payments from the tax office is a smart suggestion from public policy think tank, Melbourne’s Grattan Institute, originators of another Labor policy… Read More ›
-
Admedus’s ADAPT products gaining market traction.
Australian small-cap healthcare stock Admedus now has a calendar year reporting season, and on the 28th February 2018 it accordingly announced its financial results for the second half of 2017, covering the period 30 June to 31 December 2017. Admedus has… Read More ›
-
Chart review of Propel Funeral Partners (PFP)
Occasionally, retail investors may have the opportunity to be allocated shares through their broker, in a company about to be listed on the Australian Stock Exchange (ASX). The greatest attraction of taking up the offer is the opportunity to make… Read More ›
-
A recession proof industry? Chart review of Invocare (IVC)
I wish I had invested in ASX listed funeral industry stock Invocare, along with Healthcare stock CSL prior to the GFC, since both have still continued to trend upwards, when nearly every other stock dived. Both are still worth including… Read More ›
-
New Hills Facility opening at Seven Hills – Chart Review of HIL
There can be no doubting the power of news releases, whether unbiased and factual, or based largely on supposition, to motivate market participants, and influence company price action. This daily candlestick chart (Chart 1), extending over the past year, illustrates… Read More ›
-
Plan your strategy for the downturn now!
So far it has only been a two trading day correction, but the severity of the share-market fall emanating from the US, is deeply concerning for Australian retail investors, particularly retirees. The chart below is a 5 year weekly candle-stick… Read More ›
-
Hemp Seed Honey! Chart review of Eve Investments (EVE).
https://www.businessinsider.com.au/australian-made-cannabis-honey-is-coming-soon-2017-11 It may not have the euphoric properties of smoking cannabis, but a new honey product has been formulated which incorporates the seeds of hemp plants in honey, and is claimed to have nutritional and health benefits, as well as… Read More ›
-
Taking profit along the way with Admedus (AHZ)
The daily chart above displays the price action of emerging health-care stock Admedus, a stock I have frequently reviewed over the past 5 years on this blog. It has promised much, but the share-price has gone nowhere in that time,… Read More ›
-
Who wants to win or lose on Health-Care Stocks? The Sirtex (SRX) saga draws to an end.
https://technicality.me/2016/12/19/chart-review-sirtex-srx/ There is, it would seem, a happy ending for disgruntled shareholders of beleaguered health-care stock Sirtex. After all the to-ing and fro-ing, the cash offer of $28 per share from global healthcare stock Varian Medical Systems, is a great… Read More ›
